News
Zacks Investment Research on MSN3h
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Johnson & Johnson JNJ announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its ...
The submission is supported by four Phase III clinical trials, which showed that icotrokinra demonstrated significant skin ...
Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated ...
SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...
Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key ...
An FDA advisory panel will meet July 18 to consider a supplemental new drug application for the antipsychotic brexpiprazole, ...
The US Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ...
The Trump administration’s proposed cuts at the National Institutes of Health and Food and Drug Administration could lower ...
The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...
The U.S. Food and Drug Administration named ex-biotech exec George Tidmarsh as its chief drug regulator. FDA Commissioner ...
An analysis from the Congressional Budget Office warns that cuts to the National Institutes of Health and FDA drug reviews could significantly reduce the number of new medications reaching the U.S.
A new report looks at hiring trends © 2025 American City Business Journals. All rights reserved. Use of and/or registration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback